Improving T cell responses to modified peptides in tumor vaccines

Once a killer, always a killer: from cytotoxic T cell to memory cell

(2015) Leo Lefrançois et al.   IMMUNOLOGICAL REVIEWS

MHC Variant Peptide-Mediated Anergy of Encephalitogenic T Cells Requires SHP-1

(2014) H. A. Wasserman et al.   JOURNAL OF IMMUNOLOGY

Distinct CD8+ T Cell Repertoires Primed with Agonist and Native Peptides Derived from a Tumor-Associated Antigen

(2014) Y. Hou et al.   JOURNAL OF IMMUNOLOGY

Dissection of T-cell Antigen Specificity in Human Melanoma

(2012) R. S. Andersen et al.   CANCER RESEARCH

HLA Anchor Optimization of the Melan-A-HLA-A2 Epitope within a Long Peptide Is Required for Efficient Cross-Priming of Human Tumor-Reactive T Cells

(2012) J.-M. Chauvin et al.   JOURNAL OF IMMUNOLOGY

Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting

(2012) Hirokazu Matsushita et al.   NATURE

VEGF-C Promotes Immune Tolerance in B16 Melanomas and Cross-Presentation of Tumor Antigen by Lymph Node Lymphatics

(2012) Amanda W. Lund et al.   Cell Reports

T Cell Receptor Signaling Is Limited by Docking Geometry to Peptide-Major Histocompatibility Complex

(2011) Jarrett J. Adams et al.   IMMUNITY

CD8+ T Cells: Foot Soldiers of the Immune System

(2011) Nu Zhang et al.   IMMUNITY

Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication

(2011) Sergio A. Quezada et al.   IMMUNOLOGICAL REVIEWS

A Single Autoimmune T Cell Receptor Recognizes More Than a Million Different Peptides

(2011) Linda Wooldridge et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Randomized Multicenter Trial of the Effects of Melanoma-Associated Helper Peptides and Cyclophosphamide on the Immunogenicity of a Multipeptide Melanoma Vaccine

(2011) Craig L. Slingluff et al.   JOURNAL OF CLINICAL ONCOLOGY

Elevated Tumor-Associated Antigen Expression Suppresses Variant Peptide Vaccine Responses

(2011) C. B. Kemmler et al.   JOURNAL OF IMMUNOLOGY

Minimal Tolerance to a Tumor Antigen Encoded by a Cancer-Germline Gene

(2011) I. J. Huijbers et al.   JOURNAL OF IMMUNOLOGY

Sequential Administration of the Native TERT572 Cryptic Peptide Enhances the Immune Response Initiated by its Optimized Variant TERT572Y in Cancer Patients

(2011) Eleni-Kyriaki Vetsika et al.   JOURNAL OF IMMUNOTHERAPY

Cancer immunotherapy comes of age

(2011) Ira Mellman et al.   NATURE

Translating Tumor Antigens into Cancer Vaccines

(2010) Luigi Buonaguro et al.   Clinical and Vaccine Immunology

Therapeutic cancer vaccines: are we there yet?

(2010) Christopher A. Klebanoff et al.   IMMUNOLOGICAL REVIEWS

Lymph node–resident lymphatic endothelial cells mediate peripheral tolerance via Aire-independent direct antigen presentation

(2010) Jarish N. Cohen et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Ca 2+ Release from the Endoplasmic Reticulum of NY-ESO-1–Specific T Cells Is Modulated by the Affinity of TCR and by the Use of the CD8 Coreceptor

(2010) Ji-Li Chen et al.   JOURNAL OF IMMUNOLOGY

Modification of MHC Anchor Residues Generates Heteroclitic Peptides That Alter TCR Binding and T Cell Recognition

(2010) D. K. Cole et al.   JOURNAL OF IMMUNOLOGY

Structures of native and affinity-enhanced WT1 epitopes bound to HLA-A0201: Implications for WT1-based cancer therapeutics

(2010) Oleg Y. Borbulevych et al.   MOLECULAR IMMUNOLOGY

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Peptide vaccines prevent tumor growth by activating T cells that respond to native tumor antigens

(2010) K. R. Jordan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity

(2010) Daniel E. Speiser et al.   SEMINARS IN IMMUNOLOGY

Lymph node stroma broaden the peripheral tolerance paradigm

(2010) Anne L. Fletcher et al.   TRENDS IN IMMUNOLOGY

Attenuated T Cell Responses to a High-Potency Ligand In Vivo

(2010) Emily Corse et al.   PLOS BIOLOGY

Antigen sensitivity is a major determinant of CD8+ T-cell polyfunctionality and HIV-suppressive activity

(2009) J. R. Almeida et al.   BLOOD

Fine Structural Variations of   TCRs Selected by Vaccination with Natural versus Altered Self-Antigen in Melanoma Patients

(2009) S. Wieckowski et al.   JOURNAL OF IMMUNOLOGY

Complete but curtailed T-cell response to very low-affinity antigen

(2009) Dietmar Zehn et al.   NATURE

Immunosuppressive mechanisms in cancer: Consequences for the development of therapeutic vaccines

(2009) Stefanie Gross et al.   VACCINE

Immune Therapy for Cancer

(2008) Michael Dougan et al.   Annual Review of Immunology

Modified peptides in anti-cancer vaccines: are we eventually improving anti-tumour immunity?

(2008) Manuela Iero et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Epitope Landscape in Breast and Colorectal Cancer

(2008) N. H. Segal et al.   CANCER RESEARCH

The good, the bad and the ugly: how altered peptide ligands modulate immunity

(2008) Maria Katsara et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

T-cell receptor binding affinities and kinetics: impact on T-cell activity and specificity

(2008) Jennifer D. Stone et al.   IMMUNOLOGY

CD8+ T cell efficacy in vaccination and disease

(2008) Victor Appay et al.   NATURE MEDICINE

A Simple Detection Method for Low-Affinity Membrane Protein Interactions by Baculoviral Display

(2008) Toshiko Sakihama et al.   PLoS One

Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen

(2008) D. E. Speiser et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Age-dependent tolerance to an endogenous tumor-associated antigen

(2008) Jennifer A. McWilliams et al.   VACCINE